Placebo-controlled double-blind trial of pirprofen and an ergotamine tartrate compound in migraine attacks.
Sixty-one patients, 16 with classic and 45 with common migraine, were treated during three subsequent attacks with pirprofen, a new inhibitor of prostaglandin synthesis; an ergotamine tartrate compound; or placebo, in a randomized, double-blind multicentre study. Pain relief after a single dose and reduction of the attack intensity occurred most often with pirprofen in patients who needed more than one dose. Among them, however, the duration of attack was shortest with ergotamine. Working ability was well preserved with pirprofen, especially among patients with common migraine, and this treatment was ranked highest by the patients. However, no statistically significant differences were found between pirprofen and ergotamine. No serious side effects were observed with pirprofen. This study establishes the usefulness of pirprofen in the treatment of acute migraine.
D000293:Adolescent; D000328:Adult; D004311:Double-Blind Method; D004878:Ergotamine; D004879:Ergotamines / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*; D010666:Phenylpropionates / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos
D004879:Ergotamines; D010666:Phenylpropionates; D010919:Placebos; D004878:Ergotamine; C008924:pirprofen